Key Factors in Clinical Protocols for Adoptive Cell Therapy in Melanoma.
Key Factors in Clinical Protocols for Adoptive Cell Therapy in Melanoma.
复制标题
黑色素瘤过继细胞治疗临床方案的关键因素。
DOI：
10.1007/978-1-0716-0203-4_20
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Hurwitz,MichaelE
中科院分区：
文献类型：
--
作者：
Considine,Bryden;Hurwitz,MichaelE
使用自体肿瘤浸润淋巴细胞（TIL）的抗肿瘤细胞疗法（ACT）已经在晚期转移性癌症（主要是黑色素瘤）患者中研究了数十年，并且在此期间发生了显著变化。用TIL治疗包括离体细胞活化和扩增，然后将这些细胞再输注到患者体内。细胞输注后，患者接受白细胞介素-2（IL-2）。转移性黑色素瘤患者的客观缓解率高达52%。改善TIL疗法的努力包括更好地选择和扩增肿瘤反应性淋巴细胞，优化IL-2或其他T细胞活化细胞因子剂量，以及潜在地对免疫细胞产物进行遗传操作。在这里，我们描述的方法涉及收集，扩增，并与TIL的转移性黑色素瘤患者的治疗。
Adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) has been studied for patients with advanced metastatic cancers (primarily melanoma) for decades and has changed significantly during that period. Treatment with TIL includes ex vivo cell activation and expansion followed by re-infusion of these cells into the patient. After cell infusion, patients receive Interleukin-2 (IL-2). Objective response rates up to 52% have been seen in patients with metastatic melanoma. Efforts to improve TIL therapy include better selection and expansion of tumor-reactive lymphocytes, optimization of IL-2 or other T cell activating cytokine dosing, and, potentially, genetic manipulation of the immune cell product. Here we describe methods involved in the collection, expansion, and treatment with TIL for patients with metastatic melanoma.